| Display title | Chemistry:Technetium (99mTc) sulesomab |
| Default sort key | Technetium (99mTc) sulesomab |
| Page length (in bytes) | 6,564 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 330351 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>Scavis2 |
| Date of page creation | 08:38, 6 March 2023 |
| Latest editor | imported>Scavis2 |
| Date of latest edit | 08:38, 6 March 2023 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Technetium (99mTc) sulesomab (trade name LeukoScan) is a radio-pharmaceutical composed of anti-human mouse monoclonal antibody that targets the granulocyte associated NCA-90 cell antigen and a conjugated technetium-99m radionuclide. After intravenous administration, Leukoscan enables sensitive and specific... |
